Grifols SA is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, while the stock currently trades around $8.25—well below the average analyst price target of $10.87.
The central focus for investors this quarter is the company’s deleveraging trajectory and its target for a 4.2x leverage ratio by year-end.
Following recent governance changes and cost-cutting initiatives, the market is looking for sustained free cash flow growth to validate the operational recovery. Supporting this trend is the continued expansion of the high-margin immunoglobulin franchise and the successful integration of plasma collection centers in emerging markets like Egypt.